Table 3 Associations between MMR gene polymorphisms and platinum-based chemotherapy toxicity in the 220 NSCLC patients

Overall

MSH2

rs6544991

1.18 (0.77–1.79)

0.447

1.39 (0.76–2.55)

0.290

1.02 (0.44–2.33)

0.973

MSH3

rs6151627

1.20 (0.77–1.86)

0.419

1.49 (0.83–2.65)

0.181

0.77 (0.27–2.17)

0.618

rs6151670

1.14 (0.73–1.76)

0.572

1.37 (0.76–2.45)

0.293

0.75 (0.27–2.13)

0.593

rs7709909

1.21 (0.79–1.87)

0.380

1.51 (0.84–2.71)

0.163

0.83 (0.31–2.19)

0.703

MSH5

rs707939

0.45 (0.28–0.73)

0.001

0.42 (0.23–0.76)

0.004

0.27 (0.09–0.84)

0.023

rs805304

1.66 (1.04–2.65)

0.034

2.21 (1.19–4.09)

0.012

1.21 (0.44–3.34)

0.716

Hematologic

MSH2

rs6544991

1.01 (0.64–1.61)

0.957

0.97 (0.50–1.87)

0.919

1.12 (0.45–2.77)

0.805

MSH3

rs6151627

1.55 (0.96–2.50)

0.074

2.38 (1.23–4.60)

0.010

0.75 (0.23–2.44)

0.635

rs6151670

1.42 (0.88–2.29)

0.153

2.05 (1.07–3.93)

0.032

0.75 (0.23–2.43)

0.630

rs7709909

1.55 (0.97–2.49)

0.067

2.38 (1.23–4.64)

0.010

0.87 (0.30–2.58)

0.808

MSH5

rs707939

0.68 (0.41–1.12)

0.128

0.66 (0.35–1.28)

0.219

0.50 (0.16–1.54)

0.225

rs805304

1.37 (0.83–2.27)

0.223

1.99 (1.01–3.90)

0.047

0.60 (0.16–2.20)

0.436

Gastrointestinal

MSH2

rs6544991

1.56 (0.90–2.69)

0.113

2.98 (1.20–7.40)

0.019

0.88 (0.28–2.76)

0.827

MSH3

rs6151627

0.63 (0.33–1.20)

0.161

0.54 (0.24–1.19)

0.128

0.66 (0.14–3.02)

0.592

rs6151670

0.67 (0.35–1.27)

0.220

0.59 (0.27–1.32)

0.199

0.64 (0.14–2.94)

0.568

rs7709909

0.62 (0.33–1.18)

0.145

0.55 (0.25–1.20)

0.132

0.58 (0.13–2.63)

0.481

MSH5

rs707939

0.46 (0.24–0.88)

0.020

0.44 (0.20–0.96)

0.038

0.21 (0.03–1.65)

0.139

rs805304

1.64 (0.90–2.97)

0.105

1.86 (0.83–4.20)

0.133

1.85 (0.56–6.14)

0.314